Friday, August 13, 2021 9:49:55 PM
It’s not just my defense.
Thanks.
My arguments are pretty standard within the academic community. Every scientific study, and its consequent paper, has to stand up to intense questioning by fellow scholars. Anyone who’s defended a master’s or doctoral thesis knows the game. The candidate does a study, then very carefully tells all that was discovered. Finally, academic advisors, in a formal event, try to disqualify both the paper and the candidate, by asking every sort of question about study and the paper. “Mr. Jones, how could you claim that ... is valid? Aren’t you familiar with Dr. Dorgalson’s work showing exactly opposite of what you claim?”
Contesting verbal, argumentative pokes and jabs about everything in the paper. Get something wrong, or fail to verbally defend it, and start all over.
That’s how science works. Don’t accept anything without actual experimental data that substantiate the validity of new ideas.
My point is this. Yes, I’m a retired high school advanced placement biology teacher, now conducting high-level, world-class ecological studies at a university, which will solve a major ecological problem. At every step, I’ve had to answer the “How can it be....?” questions. That’s what good scientists do. Try to find why some new concept or protocol is invalid. No one is finding any of that with blarcamesine. There are lots of academic and medical science professionals scrutinizing the expanding Anavex story. They, too, can’t find anything wrong with Anavex science. Their silence on the matter is definitive.
Best defense of our drug I’ve ever heard.
Thanks.
My arguments are pretty standard within the academic community. Every scientific study, and its consequent paper, has to stand up to intense questioning by fellow scholars. Anyone who’s defended a master’s or doctoral thesis knows the game. The candidate does a study, then very carefully tells all that was discovered. Finally, academic advisors, in a formal event, try to disqualify both the paper and the candidate, by asking every sort of question about study and the paper. “Mr. Jones, how could you claim that ... is valid? Aren’t you familiar with Dr. Dorgalson’s work showing exactly opposite of what you claim?”
Contesting verbal, argumentative pokes and jabs about everything in the paper. Get something wrong, or fail to verbally defend it, and start all over.
That’s how science works. Don’t accept anything without actual experimental data that substantiate the validity of new ideas.
My point is this. Yes, I’m a retired high school advanced placement biology teacher, now conducting high-level, world-class ecological studies at a university, which will solve a major ecological problem. At every step, I’ve had to answer the “How can it be....?” questions. That’s what good scientists do. Try to find why some new concept or protocol is invalid. No one is finding any of that with blarcamesine. There are lots of academic and medical science professionals scrutinizing the expanding Anavex story. They, too, can’t find anything wrong with Anavex science. Their silence on the matter is definitive.
Recent AVXL News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
